Literature DB >> 3554695

Intravesical therapy. A critical review.

H W Herr.   

Abstract

In order to determine the effectiveness of intravesical therapy for superficial bladder cancer, the author critically reviews current data and the methodology upon which such data are based. Included is a discussion of prophylactic versus therapeutic intravesical therapy, the design of clinical trials for intravesical therapy and endpoints of response, biostatistical considerations, a review of randomized clinical trials, and selection of patients for intravesical therapy.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3554695

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN： 0094-0143            Impact factor:   2.241


  6 in total

Review 1.  Intravesical drug delivery. Pharmacokinetic and clinical considerations.

Authors:  M S Highley; A T van Oosterom; R A Maes; E A De Bruijn
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

2.  Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma.

Authors:  R Paroni; A Salonia; A Lev; L F Da Pozzo; G Cighetti; F Montorsi; P Rigatti; R Colombo
Journal:  Br J Clin Pharmacol       Date:  2001-09       Impact factor: 4.335

3.  Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical mitomycin C therapy for superficial bladder cancer.

Authors:  M G Wientjes; R A Badalament; J L Au
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

4.  Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors.

Authors:  Ralph Madeb; Dragan Golijanin; Katia Noyes; Susan Fisher; Judith J Stephenson; Stacey R Long; Joy Knopf; Gary H Lyman; Edward M Messing
Journal:  Cancer       Date:  2009-06-15       Impact factor: 6.860

5.  Selection of patients for intravesical therapy for superficial bladder cancer.

Authors:  Y Bedük; L S Yaman; S Baltaci; Y Z Müftüoğlu; T Yurdakul; O Göğüş
Journal:  Int Urol Nephrol       Date:  1994       Impact factor: 2.370

6.  A novel strategy for NQO1 (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9.

Authors:  G A Choudry; P A Stewart; J A Double; M R Krul; B Naylor; G M Flannigan; T K Shah; J E Brown; R M Phillips
Journal:  Br J Cancer       Date:  2001-10-19       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.